PAD-LOCK
Dead / Abandoned — Abandoned — failure to respond (as of 09 Jan 2024)
What this means for you
This application is over — abandoned 26 Dec 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97716190
- Mark type
- Stylized text
- Filed
- 13 Dec 2022
- Abandoned
- 26 Dec 2023
- Attorney of record
- Alyssa M Worsham
Goods and services
- Class 001 — Chemicals: Chemical products for use in industry and science; reagents for use in scientific apparatus for chemical or biological analysis; reagents for medical research; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use
- Class 005 — Pharmaceuticals: Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologics; pharmaceutical products, namely, covalent protein drugs; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologics; pharmaceutical products consisting of covalent protein drugs; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals
- Class 042 — Scientific and technological services: Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, synthetic chemistry, recombinant protein production, bioconjugation, testing, and analysis; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies
Owner
- Enlaza Therapeutics, Inc., La Jolla, CA, US
Prosecution history
- 09 Jan 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 09 Jan 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 09 Jan 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 23 Sept 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 23 Sept 2023 — NON-FINAL ACTION E-MAILED
- 23 Sept 2023 — NON-FINAL ACTION WRITTEN
- 16 Sept 2023 — ASSIGNED TO EXAMINER
- 10 Jan 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 16 Dec 2022 — NEW APPLICATION ENTERED